Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis
- PMID: 19528350
- PMCID: PMC2708807
- DOI: 10.2353/ajpath.2009.080986
Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis
Abstract
Impairment of the colonic epithelial barrier and neutrophil infiltration are common features of inflammatory bowel disease. Luminal proteases affect colonic permeability through protease-activated receptors (PARs). We evaluated: (i) whether fecal supernatants from patients with ulcerative colitis (UC) trigger alterations of colonic paracellular permeability and inflammation, and (ii) the roles of cathepsin G (Cat-G), a neutrophil serine protease, and its selective receptor, PAR(4), in these processes. Expression levels of both PAR(4) and Cat-G were determined in colonic biopsies from UC and healthy subjects. The effects of UC fecal supernatants on colonic paracellular permeability were measured in murine colonic strips. Involvement of Cat-G and PAR(4) was evaluated using pepducin P4pal-10 and specific Cat-G inhibitor (SCGI), respectively. In addition, the effect of PAR(4)-activating peptide was assessed. UC fecal supernatants, either untreated or pretreated with SCGI, were infused into mice, and myeloperoxidase activity was determined. PAR(4) was found to be overexpressed in UC colonic biopsies. Increased colonic paracellular permeability that was triggered by UC fecal supernatants was blocked by both SCGI (77%) and P4pal-10 (85%). Intracolonic infusion of UC fecal supernatants into mice increased myeloperoxidase activity. This effect was abolished by SCGI. These observations support that both Cat-G and PAR(4) play key roles in generating and/or amplifying relapses in UC and provide a rationale for the development of new therapeutic agents in the treatment of this disease.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708807/bin/zjh0070980810001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708807/bin/zjh0070980810002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708807/bin/zjh0070980810003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708807/bin/zjh0070980810004.gif)
Similar articles
-
Intracolonic infusion of fecal supernatants from ulcerative colitis patients triggers altered permeability and inflammation in mice: role of cathepsin G and protease-activated receptor-4.Inflamm Bowel Dis. 2011 Jun;17(6):1409-14. doi: 10.1002/ibd.21454. Epub 2010 Dec 22. Inflamm Bowel Dis. 2011. PMID: 21560201
-
Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice.Pain. 2009 Jul;144(1-2):209-17. doi: 10.1016/j.pain.2009.04.017. Epub 2009 May 17. Pain. 2009. PMID: 19450926
-
Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity.Gut. 2008 May;57(5):591-9. doi: 10.1136/gut.2007.140210. Epub 2008 Jan 14. Gut. 2008. PMID: 18194983
-
Protease activated receptor 2: a new target for IBS treatment.Eur Rev Med Pharmacol Sci. 2008 Aug;12 Suppl 1:95-102. Eur Rev Med Pharmacol Sci. 2008. PMID: 18924448 Review.
-
Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.Dan Med J. 2015 Jan;62(1):B4973. Dan Med J. 2015. PMID: 25557335 Review.
Cited by
-
Discovery of Protease-Activated Receptor 4 (PAR4)-Tethered Ligand Antagonists Using Ultralarge Virtual Screening.ACS Pharmacol Transl Sci. 2024 Mar 21;7(4):1086-1100. doi: 10.1021/acsptsci.3c00378. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633591
-
Neutrophils in Inflammatory Diseases: Unraveling the Impact of Their Derived Molecules and Heterogeneity.Cells. 2023 Nov 13;12(22):2621. doi: 10.3390/cells12222621. Cells. 2023. PMID: 37998356 Free PMC article. Review.
-
A Current State of Proteomics in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Search and Review.Int J Mol Sci. 2023 May 27;24(11):9386. doi: 10.3390/ijms24119386. Int J Mol Sci. 2023. PMID: 37298338 Free PMC article. Review.
-
The emerging roles of bacterial proteases in intestinal diseases.Gut Microbes. 2023 Jan-Dec;15(1):2181922. doi: 10.1080/19490976.2023.2181922. Gut Microbes. 2023. PMID: 36843008 Free PMC article. Review.
-
PARs in the inflammation-cancer transformation of CRC.Clin Transl Oncol. 2023 May;25(5):1242-1251. doi: 10.1007/s12094-022-03052-x. Epub 2022 Dec 22. Clin Transl Oncol. 2023. PMID: 36547764 Review.
References
-
- Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429. - PubMed
-
- Robinson CE, Kottapalli V, D'Astice M, Fields JZ, Winship D, Keshavarzian A. Regulation of neutrophils in ulcerative colitis by colonic factors: a possible mechanism of neutrophil activation and tissue damage. J Lab Clin Med. 1997;130:590–602. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous